Aditxt, Inc. (ADTX)
After hours:
| Previous Close | 2.0400 |
| Open | 2.0900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.0650 - 2.1200 |
| 52 Week Range | 1.9500 - 68.0800 |
| Volume | |
| Avg. Volume | 373,055 |
| Market Cap | 3.497M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -108.1500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
MOUNTAIN VIEW, Calif., May 03, 2024--In the first and second paragraphs, shares of common stock should read: 1.6 million, (instead of 1.65 million). Second paragraph, second sentence, the conversion price of the Series C-1 Convertible Preferred Stock should read: $2.595 per share (instead of $2.47 per share). In the second paragraph, fourth sentence, the warrant exercise price should read: $2.47 (instead of $2.595 per share).
- Business Wire
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
MOUNTAIN VIEW, Calif., April 02, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agree
PR NewswireEvofem Reports $18.2 million of Phexxi Net Product Sales in 2023
The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:
